Email this article Metachronous development of breast and prostate cancer (case report)
- Authors: Gordiev M.G.1, Druzhkov M.O.2, Dulesova A.Y.3, Nikitin A.G.4, Ulyanin M.Y.5,6, Platonova E.V.7, Brovkina O.I.4
-
Affiliations:
- Medical Diagnostic Center, Medical Institute named after Berezin Sergey
- Druzhkov's Clinic
- Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan
- Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical and Biological Agency of Russia
- Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan
- Kazan (Volga Region) Federal University
- Reedsense Genomic Center
- Issue: Vol 17, No 4 (2021)
- Pages: 151-156
- Section: CLINICAL NOTES
- Published: 10.12.2021
- URL: https://oncourology.abvpress.ru/oncur/article/view/1481
- DOI: https://doi.org/10.17650/1726-9776-2021-17-4-151-156
- ID: 1481
Cite item
Full Text
Abstract
The formation of primary multiple malignant neoplasms, such as breast cancer and prostate cancer, in one patient is a rather rare combination. Treatment and diagnostic strategies in such cases require a multidisciplinary approach. Currently, there are no approved recommendations for the management of patients with a combination of these diseases. This manuscript presents a clinical case of diagnosis and treatment of breast and prostate cancer in one patient.
About the authors
M. G. Gordiev
Medical Diagnostic Center, Medical Institute named after Berezin Sergey
Email: marat7925@gmail.com
ORCID iD: 0000-0002-3848-865X
Build. 3A, 2 Yesenina St., Saint-Petersburg 194354.
Russian FederationM. O. Druzhkov
Druzhkov's Clinic
Email: m.a.x2002@mail.ru
31 Sibgata Khakima St., Kazan 420126.
Russian FederationA. Yu. Dulesova
Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Tatarstan
Email: dulesov_a@mail.ru
ORCID iD: 0000-0002-4121-9450
29 Sibirskiy Trakt St., Kazan 420029.
Russian FederationA. G. Nikitin
Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical and Biological Agency of Russia
Email: avialn@gmail.com
ORCID iD: 0000-0001-9762-3383
28 Orekhovyy Bul'var, Moscow 115682.
Russian FederationM. Yu. Ulyanin
Republican Clinical Hospital, Ministry of Health of the Republic of Tatarstan; Kazan (Volga Region) Federal University
Email: Mikhail_ulyanin@mail.ru
138 Orenburgskiy Trakt St., Kazan 420064; 18 Kremlevskaya St., Kazan 420008.
Russian FederationE. V. Platonova
Reedsense Genomic Center
Email: ix.ti.andr@mail.ru
2B Promyshlennaya St., Troitsk, Moscow 142190.
Russian FederationO. I. Brovkina
Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies of the Federal Medical and Biological Agency of Russia
Author for correspondence.
Email: brov.olia@gmail.com
ORCID iD: 0000-0002-0946-7331
Ol'ga I. Brovkina.
28 Orekhovyy Bul'var, Moscow 115682.
Russian FederationReferences
- Axel E.M., Matveev V.B. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15-24. (In Russ.). doi: 10.17650/1726-97762019-15-2-15-24.
- Konduri S., Singh M., Bobustuc G. et al. Epidemiology of male breast cancer. Breast 2020;54:8-14. doi: 10.1016/j.breast.2020.08.010.
- Hemminki K., Forsti A., Chen B. Breast and prostate cancer: familial associations. Nat Rev Cancer 2010;10(7):523. doi: 10.1038/nrc2795-c1.
- Fedier A., Fink D. Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 2004;24(4):1039-47.
- Risbridger G.P., Davis I.D., Birrell S.N., Tilley W.D. Breast and prostate cancer: more similar than different. Nat Rev Cancer 2010;10(3):205-12. doi: 10.1038/nrc2795.
- Ferla R., Calo V., Cascio S. et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;18 Suppl 6:vi93-8. doi: 10.1093/annonc/mdm234.
- Fackenthal J.D., Olopade O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007;7(12):937-48. doi: 10.1038/nrc2054.
- Stone L. The IMPACT of BRCA2 in prostate cancer. Nat Rev Urol 2019;16(11):639. doi: 10.1038/s41585-019-0249-4.
- Messina C., Cattrini C., Soldato D. et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J Oncol 2020;2020:4986365. doi: 10.1155/2020/4986365.
- Castro E., Goh C., Olmos D. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882.
- Matveev V., Lyubchenko L., Kirichek A. Impact of germline DNA-repair gene BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer: a single center analysis. J Clin Oncol 2019;37:5056. doi: 10.1200/JCO.2019.37.15_suppl.5056.
- Matveev V.B., Kirichek A.A., Filippova M.G. et al. Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-naive prostate cancer. Urologiya = Urologiia 2019;(5):79-85. (In Russ.). doi: 10.18565/urology.2019.5.79-85.
Supplementary files
